Sharemaestro company-news research for Spyre Therapeutics Inc. (SYRE), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
NASDAQ
United States
Provisional evidence
Company news sentiment
Latest SYRE news and sentiment
Spyre Therapeutics Inc.
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
Current company news
Early balanced news score
37 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone59/100
→
Published 30-day score52/100
Latest source headline
Spyre Therapeutics launches public stock offering
Investing.com · 05 Oct 2026 20:41
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
37 current stories are mapped specifically to SYRE.
The score uses 12 publishers rather than depending on one outlet.
What limits the score
The stories agree, but freshness-weighted evidence is only 0.270.
Confidence is 23/100, below the threshold for a firm score.
52/100
News scoreEarly balanced news score
23/100
Confidencethin evidence
98%/100
Company news37 company stories
86/100
Story agreement14/100 difference
News history
Daily score and story count over 30 days
11 Sep26 Sep10 Oct
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence5
0.27 after freshness weightingSource breadth100
12 independent publishersCompany relevance98
share tied directly to this companyFreshness22
recency-weighted evidenceAgreement86
how closely stories agreePublisher mix83
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks16 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr14 Jul09 Oct
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
09 Oct 202651USD 85.69-8.0%
02 Oct 202655USD 93.19+8.8%
25 Sep 202649USD 85.69-5.1%
18 Sep 202649USD 90.25-0.4%
11 Sep 202649USD 90.6+1.8%
04 Sep 202647USD 88.98-1.5%
28 Aug 202651USD 90.36-15.1%
21 Aug 202654USD 106.49+2.8%
Provisional evidence
News subjects
What is shaping the score
Market update4223 stories · 62%
Analyst action668 stories · 22%
Earnings634 stories · 11%
Regulatory and legal501 stories · 3%
Balance sheet501 stories · 3%
Source mix
Where the evidence comes from
Stock Titan495 stories · 14%
Moomoo713 stories · 8%
Investing.com383 stories · 8%
simplywall.st573 stories · 8%
GuruFocus503 stories · 8%
TradingView503 stories · 8%
Simply Wall Street512 stories · 5%
Recurring subjects
Subjects appearing most often
Life Sciences19Financial Markets15Earnings10Finance9Clinical Trials3Biotech3IPO2Technology1Fourth Quarter1
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
31 Jul50 neutral10 Oct 13:18
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 10 Oct 13:18 | 51 | +0 | 24/100 (-12) | 35 (-6) | Provisional |
| 05 Oct 23:59 | 51 | -1 | 36/100 (-2) | 41 (-1) | Measured |
| 04 Oct 23:59 | 52 | +1 | 38/100 (-2) | 42 (-5) | Measured |
| 03 Oct 23:59 | 51 | -4 | 40/100 (+5) | 47 (+2) | Measured |
| 02 Oct 23:59 | 55 | -1 | 35/100 (-3) | 45 (+2) | Provisional |
| 01 Oct 23:59 | 56 | +3 | 38/100 (+8) | 43 (+6) | Provisional |
| 30 Sep 23:59 | 53 | +1 | 30/100 (+2) | 37 (+1) | Provisional |
| 28 Sep 23:59 | 52 | +3 | 28/100 (+10) | 36 (-11) | Provisional |
Evidence behind the direction
What drives this reading?
Shares of weighted directional evidence in 37 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.
Which subjects lean each way
A subject can carry both supportive and cautious news.
SubjectCautious ← 0 → Constructive
Analyst action5 stories
0.0%46.2%
Market update8 stories
31.4%0.0%
Earnings2 stories
1.8%20.5%
Each side uses the same scale: 0–46.2% of the retained directional evidence.
Where the influence comes from
34.0%largest publisher shareA concentrated reading can depend heavily on one publisher.
Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
36/100 tone
Market update
Spyre Therapeutics launches public stock offering
Spyre Therapeutics Inc. has announced the commencement of an underwritten public offering of its common stock, with plans to grant underwriters an option to purchase additional shares. The biotechnology company intends to use the net proceeds to advance its gastroenterology, rheumatology,…
10.3% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Spyre Therapeutics Inc. has announced the commencement of an underwritten public offering of its common stock, with plans to grant underwriters an option to purchase additional shares. The biotechnology company intends to use the net proceeds to advance its gastroenterology, rheumatology, and dermatology programs, including funding for preclinical studies, clinical trials, and late-stage development of SPY072. The offering is contingent on market conditions, and its completion, size, and terms are not guaranteed.
- Published
- 05 Oct 2026 20:41
- News subject
- Market update
- Why this score
- Dilution risk
- Company focus
- Shared story · 78%
- How it is used
- Direct company coverage
- Story strength
- Medium · 39/100
- 30-day weight
- 10.3% of directional evidence · 4.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
BiotechClinical TrialsFinanceFinancial MarketsIPOLife Sciences
72/100 tone
Wells Fargo has reiterated its Buy rating for Spyre Therapeutics (SYRE.US), maintaining its price target at $115. This suggests continued confidence from Wells Fargo in the company's financial prospects and stock performance.
19.5% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Wells Fargo has reiterated its Buy rating for Spyre Therapeutics (SYRE.US), maintaining its price target at $115. This suggests continued confidence from Wells Fargo in the company's financial prospects and stock performance.
- Published
- 04 Oct 2026 02:58
- News subject
- Analyst action
- Why this score
- Buy Rating
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 54/100
- 30-day weight
- 19.5% of directional evidence · 6.4d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Market updateNot used in direction
Spyre Therapeutics, Inc. (SYRE) stock price, news, quote and history
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 03 Oct 2026 22:10
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 6.6d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
40/100 tone
Spyre Therapeutics' chief legal officer, Heidy King-Jones, sold shares worth over $2.63 million on October 1, 2026, after exercising stock options. These transactions were executed under a Rule 10b5-1 trading plan. Despite the stock's significant surge over the past year, InvestingPro ana…
5.7% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Spyre Therapeutics' chief legal officer, Heidy King-Jones, sold shares worth over $2.63 million on October 1, 2026, after exercising stock options. These transactions were executed under a Rule 10b5-1 trading plan. Despite the stock's significant surge over the past year, InvestingPro analysis suggests it may be overvalued.
- Published
- 03 Oct 2026 06:34
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 36/100
- 30-day weight
- 5.7% of directional evidence · 7.3d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
42/100 tone
Cameron Turtle, CEO of Spyre Therapeutics Inc (SYRE), sold 15,000 shares of the company on October 1, 2026, at $92.01 per share. This transaction is part of a larger trend of insider selling at SYRE, with 30 insider sells and 0 buys over the past year. Investors are advised to consider th…
4.1% of directional evidence
Low story strength
Scoring detailsDirect company coverage
Cameron Turtle, CEO of Spyre Therapeutics Inc (SYRE), sold 15,000 shares of the company on October 1, 2026, at $92.01 per share. This transaction is part of a larger trend of insider selling at SYRE, with 30 insider sells and 0 buys over the past year. Investors are advised to consider this insider activity alongside the company's clinical pipeline progress and financial position.
- Published
- 03 Oct 2026 04:33
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 34/100
- 30-day weight
- 4.1% of directional evidence · 7.4d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife Sciences
40/100 tone
Spyre Therapeutics CEO Cameron Turtle sold 14,000 shares of SYRE stock for approximately $1.38 million on October 1, 2026, under a Rule 10b5-1 trading plan. This sale follows a significant 487% surge in the stock over the past year, though InvestingPro analysis suggests it's currently ove…
5.4% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Spyre Therapeutics CEO Cameron Turtle sold 14,000 shares of SYRE stock for approximately $1.38 million on October 1, 2026, under a Rule 10b5-1 trading plan. This sale follows a significant 487% surge in the stock over the past year, though InvestingPro analysis suggests it's currently overvalued. The company faces profitability challenges despite recent mixed clinical trial results and varying analyst ratings.
- Published
- 03 Oct 2026 02:33
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 36/100
- 30-day weight
- 5.4% of directional evidence · 7.4d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
FinanceLife Sciences
42/100 tone
Heidy King-Jones, Chief Legal Officer and Corporate Secretary of Spyre Therapeutics (SYRE), exercised options for 28,933 common shares at $14.50 per share on October 1, 2026. She subsequently sold these shares in five separate transactions under a Rule 10b5-1 trading plan, with weighted-a…
3.2% of directional evidence
Low story strength
Scoring detailsDirect company coverage
Heidy King-Jones, Chief Legal Officer and Corporate Secretary of Spyre Therapeutics (SYRE), exercised options for 28,933 common shares at $14.50 per share on October 1, 2026. She subsequently sold these shares in five separate transactions under a Rule 10b5-1 trading plan, with weighted-average sale prices ranging from $89.24 to $93.46 per share. Following these transactions, her reported post-exercise stock-option position was 482,478 underlying shares.
- Published
- 03 Oct 2026 01:33
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 32/100
- 30-day weight
- 3.2% of directional evidence · 7.5d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
Life SciencesFinancial Markets
—Unscored
Market updateNot used in direction
SYRE News | SPYRE THERAPEUTICS INC (NASDAQ:SYRE)
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 03 Oct 2026 00:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.6d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Spyre Therapeutics Announces Grants of Inducement Awards
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 02 Oct 2026 20:05
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 7.7d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
40/100 tone
Heidy King-Jones, an officer at Spyre Therapeutics (NASDAQ:SYRE), has filed a Form 144 to sell 29,335 shares of common stock, valued at over $2.6 million, under a pre-established Rule 10b5-1 trading plan. These shares will be acquired through stock option exercises. King-Jones has also ma…
2.7% of directional evidence
Low story strength
Scoring detailsDirect company coverage
Heidy King-Jones, an officer at Spyre Therapeutics (NASDAQ:SYRE), has filed a Form 144 to sell 29,335 shares of common stock, valued at over $2.6 million, under a pre-established Rule 10b5-1 trading plan. These shares will be acquired through stock option exercises. King-Jones has also made previous sales under the same plan in September 2026.
- Published
- 02 Oct 2026 01:18
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 35/100
- 30-day weight
- 2.7% of directional evidence · 8.5d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
FinanceLife Sciences
68/100 tone
J.P. Morgan has initiated coverage on Spyre Therapeutics (SYRE.US) with a "Buy" rating. The investment bank has set a target price of $110 for the company's stock. This new rating and price target indicate a positive outlook from J.P. Morgan regarding Spyre Therapeutics' future performanc…
9.4% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
J.P. Morgan has initiated coverage on Spyre Therapeutics (SYRE.US) with a "Buy" rating. The investment bank has set a target price of $110 for the company's stock. This new rating and price target indicate a positive outlook from J.P. Morgan regarding Spyre Therapeutics' future performance.
- Published
- 01 Oct 2026 23:18
- News subject
- Analyst action
- Why this score
- Buy Rating
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 45/100
- 30-day weight
- 9.4% of directional evidence · 8.6d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
FinanceFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
A passive investor reports more than 5% ownership of Spyre Therapeutics (SYRE).
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 01 Oct 2026 20:05
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
After a $2.44M September sale, an officer proposes selling more Spyre Therapeutics (SYRE) shares.
Heidy King-Jones, an officer at Spyre Therapeutics (SYRE), plans to sell 29,335 common shares worth approximately $2.61 million on October 1, 2026. This proposed sale follows two previous 10b5-1 sales by King-Jones in September 2026, totaling over $2.4 million. The shares were and will be…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Heidy King-Jones, an officer at Spyre Therapeutics (SYRE), plans to sell 29,335 common shares worth approximately $2.61 million on October 1, 2026. This proposed sale follows two previous 10b5-1 sales by King-Jones in September 2026, totaling over $2.4 million. The shares were and will be acquired through stock-option exercises.
- Published
- 01 Oct 2026 20:18
- News subject
- Market update
- Why this score
- Institutional or insider selling
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
FinanceLife Sciences
—Unscored
Analyst actionNot used in direction
Spyre stock draws new Overweight at J.P. Morgan (SYRE:NASDAQ)
J.P. Morgan initiated coverage on Spyre Therapeutics (SYRE) with an Overweight rating and a $110 price target for year-end 2027. Analyst Hardik Parikh highlighted the company's strong potential in treating inflammatory bowel disease (IBD) as the primary driver for the positive outlook. Th…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
J.P. Morgan initiated coverage on Spyre Therapeutics (SYRE) with an Overweight rating and a $110 price target for year-end 2027. Analyst Hardik Parikh highlighted the company's strong potential in treating inflammatory bowel disease (IBD) as the primary driver for the positive outlook. This news led to a rise in Spyre Therapeutics' stock price on Thursday.
- Published
- 01 Oct 2026 18:04
- News subject
- Analyst action
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.8d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
57/100 tone
4.9% of directional evidence
Low story strength
Scoring detailsDirect company coverage
- Published
- 01 Oct 2026 15:59
- News subject
- Analyst action
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 32/100
- 30-day weight
- 4.9% of directional evidence · 8.9d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Analyst actionNot used in direction
SYRE Reiterated by BTIG -- Price Target Maintained at $121
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 01 Oct 2026 15:27
- News subject
- Analyst action
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 8.9d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
69/100 tone
7.3% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
- Published
- 01 Oct 2026 09:46
- News subject
- Analyst action
- Why this score
- Analyst upgrade
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 46/100
- 30-day weight
- 7.3% of directional evidence · 9.1d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
SYRE Stock Steadies As SPY003 Trial Data De-Risks IBD Pipeline
Spyre Therapeutics (SYRE) stock is trending up after positive Phase 2 SKYLINE trial data for SPY003 in ulcerative colitis, hitting its primary endpoint and de-risking its IBD pipeline. This win, combined with validated SPY001 and SPY002, establishes a multi-mechanism IBD platform. Despite…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Spyre Therapeutics (SYRE) stock is trending up after positive Phase 2 SKYLINE trial data for SPY003 in ulcerative colitis, hitting its primary endpoint and de-risking its IBD pipeline. This win, combined with validated SPY001 and SPY002, establishes a multi-mechanism IBD platform. Despite strong data, the stock's premarket reaction was modest, and insider selling around September 1, 2026, suggests high expectations were already priced in, making SYRE a volatile but catalyst-driven stock.
- Published
- 01 Oct 2026 07:18
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.2d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
67/100 tone
Spyre Therapeutics (SYRE) saw a 5.1% increase in its stock price, likely due to sustained investor confidence following positive Phase 2 clinical trial results for its ulcerative colitis treatment, SPY003. The company announced strong 12-week topline results in early September, meeting it…
20.5% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
Spyre Therapeutics (SYRE) saw a 5.1% increase in its stock price, likely due to sustained investor confidence following positive Phase 2 clinical trial results for its ulcerative colitis treatment, SPY003. The company announced strong 12-week topline results in early September, meeting its primary endpoint and demonstrating clinical remission and endoscopic improvement. Despite significant insider selling over the past six months, institutional investors have shown mixed activity, with some adding substantial shares while others reduced their positions.
- Published
- 30 Sep 2026 21:20
- News subject
- Earnings
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 51/100
- 30-day weight
- 20.5% of directional evidence · 9.7d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Market updateNot used in direction
A 17,500-share sale is proposed by Spyre Therapeutics (Nasdaq: SYRE) officer Scott Burrows.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 30 Sep 2026 20:03
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.7d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
SYRE Stock Steadies As SPY003 Data Resets Biotech Expectations
Spyre Therapeutics (SYRE) stock is up 5.22% after positive Phase 2 SKYLINE data for its SPY003 drug, which met its primary endpoint for ulcerative colitis. Despite the strong clinical results, shares traded modestly lower initially, suggesting high market expectations and a "wait and see"…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Spyre Therapeutics (SYRE) stock is up 5.22% after positive Phase 2 SKYLINE data for its SPY003 drug, which met its primary endpoint for ulcerative colitis. Despite the strong clinical results, shares traded modestly lower initially, suggesting high market expectations and a "wait and see" approach from traders for combination therapy and later-stage data. The company has a strong balance sheet with over $1.1B in cash, enabling continued pipeline development, and has upcoming Phase 2 readouts for SPY072 in late 2026.
- Published
- 30 Sep 2026 19:02
- News subject
- Market update
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 9.8d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Regulatory and legalNot used in direction
Spyre Therapeutics (SYRE) Stock Price, News & Analysis
Spyre Therapeutics (SYRE) is a clinical-stage biotechnology company developing long-acting antibodies for inflammatory bowel disease (IBD) and rheumatic diseases. The company's pipeline includes investigational antibodies SPY001, SPY002, SPY072, and SPY003, designed for infrequent subcuta…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Spyre Therapeutics (SYRE) is a clinical-stage biotechnology company developing long-acting antibodies for inflammatory bowel disease (IBD) and rheumatic diseases. The company's pipeline includes investigational antibodies SPY001, SPY002, SPY072, and SPY003, designed for infrequent subcutaneous dosing, and it is exploring rational combinations of these therapies. Recent news highlights include positive Part A induction results for SPY003 and progress in its SKYLINE and SKYWAY Phase 2 clinical trials.
- Published
- 28 Sep 2026 13:31
- News subject
- Regulatory and legal
- Why this score
- Positive financial language
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 12.0d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
72/100 tone
JonesTrading has reaffirmed its Buy rating for Spyre Therapeutics (SYRE.US) and maintained its target price at $121. This indicates continued confidence from the firm in the company's prospects and valuation.
5.2% of directional evidence
Medium story strength
Scoring detailsDirect company coverage
JonesTrading has reaffirmed its Buy rating for Spyre Therapeutics (SYRE.US) and maintained its target price at $121. This indicates continued confidence from the firm in the company's prospects and valuation.
- Published
- 28 Sep 2026 09:58
- News subject
- Analyst action
- Why this score
- Buy Rating
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Medium · 48/100
- 30-day weight
- 5.2% of directional evidence · 12.1d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
Financial MarketsLife Sciences
—Unscored
Market updateNot used in direction
SYRE News | SPYRE THERAPEUTICS INC (NASDAQ:SYRE)
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 26 Sep 2026 00:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 14.6d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Spyre Therapeutics (SYRE) Dropped, So What Is Behind The Latest Attention?
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 24 Sep 2026 07:00
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 16.3d old
- Text assessed
- Available headline and article text
- Duplicates
- 1 consolidated
—Unscored
Market updateNot used in direction
Total liabilities of Spyre Therapeutics, Inc – MUN:3920
This page provides financial information for Spyre Therapeutics, Inc (MUN:3920) on TradingView, specifically focusing on its total liabilities. It outlines where the data is sourced from, including ICE Data Services and FactSet, and notes the market status as closed with no trades.
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This page provides financial information for Spyre Therapeutics, Inc (MUN:3920) on TradingView, specifically focusing on its total liabilities. It outlines where the data is sourced from, including ICE Data Services and FactSet, and notes the market status as closed with no trades.
- Published
- 23 Sep 2026 13:31
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.0d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
FinanceLife Sciences
—Unscored
Analyst actionNot used in direction
Spyre Therapeutics, Inc. (SYRE) Stock Price, News, Quote & History
This article provides a detailed financial overview of Spyre Therapeutics, Inc. (SYRE), including its current stock price, historical data, key financial metrics, and analyst insights. It highlights the company's focus on developing therapeutics for inflammatory bowel disease and rheumati…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides a detailed financial overview of Spyre Therapeutics, Inc. (SYRE), including its current stock price, historical data, key financial metrics, and analyst insights. It highlights the company's focus on developing therapeutics for inflammatory bowel disease and rheumatic diseases, outlining its primary drug candidates and their development stages. The report also covers Spyre Therapeutics' significant year-to-date and 1-year stock performance.
- Published
- 23 Sep 2026 09:22
- News subject
- Analyst action
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.2d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinancial MarketsLife Sciences
—Unscored
Market updateNot used in direction
What Does Spyre Therapeutics (SYRE) Part A Trial Success Mean For Ulcerative Colitis?
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
- Published
- 22 Sep 2026 16:16
- News subject
- Market update
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 17.9d old
- Text assessed
- Stored headline only
- Duplicates
- 1 consolidated
—Unscored
EarningsNot used in direction
Spyre Therapeutics, Inc Income Statement – MUN:3920
This article provides an income statement overview for Spyre Therapeutics, Inc. (MUN:3920), detailing key financial metrics from 2014 to 2025. It presents annual and quarterly earnings reports to help users understand the company's performance, including revenue, expenses, and profit figu…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides an income statement overview for Spyre Therapeutics, Inc. (MUN:3920), detailing key financial metrics from 2014 to 2025. It presents annual and quarterly earnings reports to help users understand the company's performance, including revenue, expenses, and profit figures, although most detailed financial data for the listed years is currently unavailable.
- Published
- 22 Sep 2026 02:58
- News subject
- Earnings
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 18.4d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinanceFinancial Markets
—Unscored
Balance sheetNot used in direction
Price to cash flow ratio of Spyre Therapeutics, Inc – MUN:3920
This article provides financial information for Spyre Therapeutics, Inc. (MUN:3920) on TradingView, specifically focusing on its price-to-cash flow ratio. It indicates that the market is currently closed with no trades. The content primarily consists of navigation and platform features wi…
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
This article provides financial information for Spyre Therapeutics, Inc. (MUN:3920) on TradingView, specifically focusing on its price-to-cash flow ratio. It indicates that the market is currently closed with no trades. The content primarily consists of navigation and platform features with limited actual financial data presented directly.
- Published
- 21 Sep 2026 09:50
- News subject
- Balance sheet
- Why this score
- No clear directional signal in the available text
- Company focus
- Main company · 100%
- How it is used
- Shown as company news · not used in the score
- Story strength
- Not directional
- 30-day weight
- None · 19.1d old
- Text assessed
- Stored article
- Duplicates
- 1 consolidated
EarningsFinanceFinancial MarketsLife SciencesTechnology
Earlier company news
SYRE news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 126 older SYRE headlines. Open one page at a time when you need them.
Open older archiveProvider matches checked
Provider mentions not used in the score
A news provider linked these stories to SYRE, but the headline and available text are not mainly about Spyre Therapeutics Inc.. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.
Provider mentions are kept separate
Open the list to see which provider matches were checked and left out of SYRE sentiment.
Open provider mentionsHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.